Clinical Study Evaluating the Effects of First-line Oral cOmbination theraPy of maciTentan and tadalafIl in Patients With Newly Diagnosed pulMonary Arterial Hypertension (OPTIMA) (OPTIMA)

Study Description

Go to 

Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Brief Summary:

The purpose of the study is to document the effect of first line dual oral combination therapy with macitentan 10mg and tadalafil 40mg on pulmonary vascular resistance (PVR) in treatment-naïve patients with newly diagnosed pulmonary arterial hypertension (PAH).

Condition or disease	Intervention/treatment	Phase
Pulmonary Arterial Hypertension	Drug: macitentan; Drug: tadalafil	Phase 4

Study Design

Go to 

Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Study Type :	Interventional (Clinical Trial)
Estimated Enrollment :	60 participants
Intervention Model:	Single Group Assignment
Masking:	None (Open Label)
Primary Purpose:	Treatment
Official Title:	Prospective, Multicenter, Open-label Study Evaluating the Effects of First-line Oral Combination Therapy of Macitentan and Tadalafil in Patients With Newly Diagnosed Pulmonary Arterial Hypertension (OPTIMA).
Actual Study Start Date :	September 1, 2015
Estimated Primary Completion Date :	October 1, 2018
Estimated Study Completion Date :	October 1, 2018

Arms and Interventions

Go to 

Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm	Intervention/treatment
Experimental: bitherapy; Macitentan and tadalafil	Drug: macitentan; used in open label; Drug: tadalafil; used in open label

Outcome Measures

Go to 

Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :

1. pulmonary vascular resistance (PVR) [ Time Frame: 16 weeks ]
   Change from Baseline to Week 16 in percentage of patients with clinically meaningful improvement of PVR (decrease of 30% from baseline to Week 16)

Secondary Outcome Measures :

1. mean right atrial pressure (mRAP) [ Time Frame: Week 16 ]
   Change from Baseline to Week 16 in mean right atrial pressure (mRAP)
2. 6MWD [ Time Frame: Week 16 ]
   Change from Baseline to Week 16 in 6MWD
3. level NT-proBNP [ Time Frame: Week 16 ]
   Change in NT-proBNP from baseline to Week 16
4. mean pulmonary arterial pressure (mPAP) [ Time Frame: Week 16 ]
   Change from Baseline to Week 16 in mean pulmonary arterial pressure (mPAP)
5. cardiac index (CI) [ Time Frame: Week 16 ]
   Change from Baseline to Week 16 in cardiac index (CI).
6. total pulmonary resistance (TPR) [ Time Frame: Week 16 ]
   Change from Baseline to Week 16 in total pulmonary resistance (TPR)
7. mixed venous oxygen saturation (Sv02) [ Time Frame: Week 16 ]
   Change from Baseline to Week 16 in mixed venous oxygen saturation (Sv02)
8. WHO functional class [ Time Frame: Week 16 ]
   Change from baseline to Week 16 in WHO functional class and Percentage of patients with improvement/worsening of WHO functional class from baseline to Week 16
9. Number of treatment goals [ Time Frame: Week 16 ]
   Number of treatment goals (score 0 or 1 per goal, i.e. total score 0-5) met at Week 16: WHO-FC I or II; Cardiac index > 2.8 L/min/m²; mRAP < 8 mmHg; 6MWD > 400 m; NT-proBNP < 3xULN

Eligibility Criteria

Go to 

Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Ages Eligible for Study:	18 Years to 75 Years (Adult, Older Adult)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria :

1. Signed informed consent prior to any study-mandated procedure.
2. Male or female ≥ 18 and ≤ 75 years of age at screening.
3. Initial PAH diagnosis < 6 months prior to Day 1.

4. Right heart catheterization (RHC) performed between Day -28 and Day 1 (RHC data obtained at the study site within this time frame, but before the study, i.e., before signed informed consent, are acceptable), meeting all the following criteria:

   • Resting mean pulmonary arterial pressure (mPAP) ≥ 25 mmHg.
   • Pulmonary capillary wedge pressure (PCWP) or left ventricular end diastolic pressure (LVEDP) ≤ 15 mmHg.
   • PVR ≥ 400 dyn·sec/cm5 (≥ 5 Wood units) if PCWP < 12 mmHg OR PVR ≥ 500 dyn·sec/cm5 (≥ 6.25 Wood units) if PCWP in [12-15] mmHg.
   • Negative vasoreactivity test mandatory in idiopathic PAH (at this or a previous RHC).
5. World Health Organization (WHO) Functional Class (FC) II to III.

6. PAH etiology belonging to one of the following groups:

   • Idiopathic.
   • Heritable.
   • Anorexigens induced.

   • Associated with one of the following:

     • Connective tissue disease
     • Congenital heart disease with simple systemic-to-pulmonary shunt (atrial septal defect, ventricular septal defect, patent ductus arteriosus) ≥1 year after surgical repair
     • HIV infection
7. 6MWD ≥ 50 m at screening.

8. Woman of childbearing potential [see definition in Section 4.5.1] must:

   • Have a negative serum pregnancy test at the screening visit and a negative urine pregnancy test at the D1 visit, and
   • Agree to perform monthly pregnancy tests up to 30 days after EOT2, and
   • Agree to use reliable contraception [defined in Section 4.5.2] from screening up to 30 days after EOT2. Reliable contraception must be started at least 11 days prior to Day 1.

Exclusion Criteria:

1. Any PAH-specific drug therapy [e.g. any endothelin receptor antagonist, phosphodiesterase-5 inhibitors (PDE-5i), soluble guanylate cyclase stimulator, prostacyclin, prostacyclin analog, or prostacyclin receptor agonist] at any time prior to Day 1 (single-dose administration for vasoreactivity testing is permitted; previous iloprost used intermittently for the treatment of digital ulcers or Raynaud's phenomenon is permitted if stopped > 6 months prior to Day 1).
2. Subjects who changed the dose or discontinued calcium channel blockers within 1 week prior to Day 1.
3. Initiation of diuretics within 1 week prior to RCH.
4. Subjects on oral diuretics in whom the dose has not been stable for at least 1 week prior to RHC.
5. Treatment with other PDE-5i for erectile dysfunction.
6. Treatment with strong inducers of CYP3A4 (e.g., carbamazepine, rifampin, rifampicin, rifabutin, rifapentin, phenobarbital, phenytoin, and St. John's wort) ≤ 28 days prior to Day 1.
7. Treatment with strong inhibitors of CYP3A4 (e.g., ketoconazole, itraconazole, voriconazole, clarithromycin, telithromycin, nefazodone, ritonavir, boceprevir, telaprevir, saquinavir, lopinavir, fosamprenavir, darunavir, tipranavir, atazanavir, nelfinavir, amprenavir, indinavir) ≤ 28 days prior to Day 1.
8. History of priapism.
9. Significant aortic and mitral valve disease requiring a specific treatment.
10. Pericardial constriction.
11. Life-threatening arrhythmia.
12. Uncontrolled hypertension.
13. Symptomatic coronary artery disease.
14. Cardio-pulmonary rehabilitation program based on exercise (planned, or started ≤ 12 weeks prior to Day 1).
15. Body mass index (BMI) > 40 kg/m2 at screening.
16. Acute myocardial infarction ≤ 12 weeks prior to Day 1.
17. Known permanent atrial fibrillation.
18. Low blood pressure < 90/50 mmHg at screening or Day 1.
19. Ongoing or planned treatment with nitrates and/or doxazosin.
20. DLCO < 40% of predicted value (eligible only if no sign of veno-occlusive disease according to adjudication committee);

21. Presence of ≥ 1 of the following signs of relevant lung disease at any time prior to Day 1:

    • FEV1/FVC < 70% and FEV1 < 65% of predicted after bronchodilator administration;
    • Total Lung Capacity (TLC) < 60% of predicted.
22. Known or suspicion of pulmonary veno-occlusive disease (PVOD).
23. Severe renal insufficiency (estimated creatinine clearance ≤ 30 mL/min/1.73m²) assessed by central laboratory at screening.
24. Ongoing or planned dialysis.
25. Documented severe hepatic impairment (with or without cirrhosis) according to National Cancer Institute organ dysfunction working group criteria, defined as total bilirubin > 3 x ULN accompanied by AST > ULN (assessed by central laboratory at screening) and/or Child-Pugh Class C.
26. Serum AST and/or ALT > 3 x ULN (assessed by central laboratory at screening).
27. Porto-pulmonary hypertension.
28. Hemoglobin < 100 g/L assessed by central laboratory at screening.
29. Hypersensitivity to any active substance or excipient of macitentan or tadalafil formulation.
30. Loss of vision in one eye because of non-arteritic anterior ischemic optic neuropathy (NAION), regardless of whether or not this episode was in connection with previous PDE-5i exposure.
31. Hereditary degenerative retinal disorders, including retinitis pigmentosa.
32. Pregnancy, breast-feeding, intention to become pregnant during the study or woman of childbearing potential not agree to use reliable method of contraception from screening up to 30 days after EOT2.
33. Hereditary problems of galactose intolerance, Lapp lactase deficiency, glucosegalactose malabsorption.
34. Any factor or condition likely to affect protocol compliance of the patient as judged by the investigator.
35. Treatment with another investigational drug (planned, or taken ≤ 12 weeks prior to Day 1).
36. Concomitant life-threatening disease with a life expectancy < 12 months.

Contacts and Locations

Go to 

Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Locations

France
Hôpital Jean Minjoz
Besançon, France, 25030
Hôpital de Haut Levêque
Bordeaux, France, 33604
Hôpital Côte de Nacre
Caen, France, 14033
CHU Site du Bocage
Dijon, France, 21079
Hôpital Albert Michallon
Grenoble, France, 38700
Hôpital Bicètre
Kremlin-Bicêtre, France, 94270
Hôpital Dupuytren
Limoges, France, 87042
Hôpital Louis Pradel
Lyon, France, 69677
Hôpital Timone Adultes
Marseille, France, 13005
Hôpital Arnaud de Villeneuve
Montpellier, France, 34929
CHR La Miletrie
Poitiers, France, 86021
Hôpital Robert Debré
Reims, France, 51092
Hôpital Pontchaillou
Rennes, France, 35033
Hôpital Charles Nicolle
Rouen, France, 76031
Hôpital Nord
Saint-Priest-en-Jarez, France, 42277
Hôpital Civil
Strasbourg, France, 67091
Hôpital Larrey
Toulouse, France, 31059
Hôpital Bretonneau
Tours, France, 37044

Sponsors and Collaborators

Actelion

More Information

Go to 

Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Responsible Party:	Actelion
ClinicalTrials.gov Identifier:	NCT02968901 History of Changes
Other Study ID Numbers:	AC-055-405
First Posted:	November 21, 2016
Last Update Posted:	September 12, 2018
Last Verified:	September 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD:	Undecided

Additional relevant MeSH terms:

Hypertension; Familial Primary Pulmonary Hypertension; Vascular Diseases; Cardiovascular Diseases; Hypertension, Pulmonary; Lung Diseases; Respiratory Tract Diseases; Tadalafil; Macitentan	Vasodilator Agents; Phosphodiesterase 5 Inhibitors; Phosphodiesterase Inhibitors; Enzyme Inhibitors; Molecular Mechanisms of Pharmacological Action; Urological Agents; Endothelin A Receptor Antagonists; Endothelin Receptor Antagonists; Endothelin B Receptor Antagonists